Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies

Robak, T, Burger, JA, Tedeschi, A et al. (23 more authors) (2018) Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies. American Journal of Hematology, 93 (11). pp. 1402-1410. ISSN 0361-8609

Abstract

Metadata

Authors/Creators:
  • Robak, T
  • Burger, JA
  • Tedeschi, A
  • Barr, PM
  • Owen, C
  • Bairey, O
  • Hillmen, P https://orcid.org/0000-0001-5617-4403
  • Simpson, D
  • Grosicki, S
  • Devereux, S
  • McCarthy, H
  • Coutre, SE
  • Quach, H
  • Gaidano, G
  • Maslyak, Z
  • Stevens, DA
  • Moreno, C
  • Gill, DS
  • Flinn, IW
  • Gribben, JG
  • Mokatrin, A
  • Cheng, M
  • Styles, L
  • James, DF
  • Kipps, TJ
  • Ghia, P
Copyright, Publisher and Additional Information: © 2018 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/.
Dates:
  • Published: November 2018
  • Accepted: 15 August 2018
  • Published (online): 20 August 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Experimental Haematology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 07 Jan 2019 16:57
Last Modified: 12 May 2019 20:51
Status: Published
Publisher: Wiley
Identification Number: https://doi.org/10.1002/ajh.25259

Share / Export

Statistics